MedTrace Logo

LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus

NCT00423215 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1007

Last updated 2009-06-15

No results posted yet for this study

Summary

The objective of this protocol is to confirm the efficacy and safety profile of Lantus in every day medical practice, in type 2 diabetic patients, have been treated with any other insulin but who did not reach the target of A1c = 7%.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin glargine (LANTUS)

The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day. Treatment duration: 4 months.

Sponsors & Collaborators

Principal Investigators

  • Nurit Tweezer-Zaks, M.D. · Sanofi

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423215 on ClinicalTrials.gov